Comments

EyePoint Pharmaceuticals

EYPTNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$8.56
-0.24-2.73%
Last update: 10:44 AM
15 minutes delayed
EyePoint Pharmaceuticals (EYPT) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$55.00
Lowest Price Target1
$26.00
Consensus Price Target1
$35.38

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock, Analyst Ratings, Price Targets, Forecasts

EyePoint Pharmaceuticals Inc has a consensus price target of $35.38 based on the ratings of 9 analysts. The high is $55 issued by Guggenheim on May 18, 2023. The low is $26 issued by JonesTrading on June 14, 2023. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and JP Morgan on June 28, 2024, June 27, 2024, and June 4, 2024, respectively. With an average price target of $30 between Chardan Capital, HC Wainwright & Co., and JP Morgan, there's an implied 250.47% upside for EyePoint Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
0
0
0
0
Mar
1
May
2
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Chardan Capital
HC Wainwright & Co.
JP Morgan
Baird
Mizuho

1calculated from analyst ratings

Analyst Ratings for EyePoint Pharmaceuticals

Buy NowGet Alert
06/28/2024Buy Now227.1%Chardan Capital
Daniil Gataulin
$28 → $28MaintainsBuyGet Alert
06/27/2024Buy Now250.47%HC Wainwright & Co.
Yi Chen
$30 → $30ReiteratesBuy → BuyGet Alert
06/20/2024Buy Now—Cantor Fitzgerald
Jennifer Kim
—Reiterates → OverweightGet Alert
06/04/2024Buy Now273.83%JP Morgan
Tessa Romero
$35 → $32MaintainsOverweightGet Alert
05/13/2024Buy Now250.47%HC Wainwright & Co.
Yi Chen
$33 → $30MaintainsBuyGet Alert
05/08/2024Buy Now343.93%Baird—$46 → $38MaintainsOutperformGet Alert
05/07/2024Buy Now227.1%Chardan Capital
Daniil Gataulin
$39 → $28MaintainsBuyGet Alert
05/07/2024Buy Now250.47%Mizuho
Graig Suvannavejh
$39 → $30MaintainsBuyGet Alert
03/08/2024Buy Now285.51%HC Wainwright & Co.
Yi Chen
$33 → $33MaintainsBuyGet Alert
02/16/2024Buy Now355.61%Mizuho
Graig Suvannavejh
$30 → $39MaintainsBuyGet Alert
01/22/2024Buy Now308.88%JP Morgan
Tessa Romero
 → $35Initiates → OverweightGet Alert
01/16/2024Buy Now285.51%HC Wainwright & Co.
Yi Chen
$35 → $33MaintainsBuyGet Alert
12/11/2023Buy Now414.02%Capital One
Zegbeh Jallah
 → $44Initiates → OverweightGet Alert
12/07/2023Buy Now250.47%Mizuho
Graig Suvannavejh
$20 → $30MaintainsBuyGet Alert
12/05/2023Buy Now308.88%HC Wainwright & Co.
Yi Chen
$25 → $35MaintainsBuyGet Alert
11/02/2023Buy Now192.06%HC Wainwright & Co.
Yi Chen
$27 → $25MaintainsBuyGet Alert
11/02/2023Buy Now133.64%Mizuho
Graig Suvannavejh
 → $20Initiates → BuyGet Alert
09/14/2023Buy Now262.15%Cantor Fitzgerald
Jennifer Kim
 → $31ReiteratesOverweight → OverweightGet Alert
09/12/2023Buy Now215.42%HC Wainwright & Co.
Yi Chen
 → $27ReiteratesBuy → BuyGet Alert
08/31/2023Buy Now262.15%Cantor Fitzgerald
Jennifer Kim
 → $31ReiteratesOverweight → OverweightGet Alert
08/03/2023Buy Now215.42%HC Wainwright & Co.
Yi Chen
 → $27ReiteratesBuy → BuyGet Alert
08/03/2023Buy Now157.01%Chardan Capital
Daniil Gataulin
 → $22ReiteratesBuy → BuyGet Alert
07/28/2023Buy Now215.42%HC Wainwright & Co.
Yi Chen
 → $27ReiteratesBuy → BuyGet Alert
06/28/2023Buy Now262.15%Cantor Fitzgerald
Jennifer Kim
 → $31ReiteratesOverweight → OverweightGet Alert
06/14/2023Buy Now203.74%JonesTrading
Sean Kim
 → $26Initiates → BuyGet Alert
06/06/2023Buy Now215.42%HC Wainwright & Co.
Yi Chen
 → $27ReiteratesBuy → BuyGet Alert
05/19/2023Buy Now215.42%HC Wainwright & Co.
Yi Chen
$25 → $27MaintainsBuyGet Alert
05/19/2023Buy Now157.01%Chardan Capital
Daniil Gataulin
$21 → $22MaintainsBuyGet Alert
05/18/2023Buy Now542.52%Guggenheim
Yatin Suneja
$52 → $55MaintainsBuyGet Alert
03/27/2023Buy Now192.06%HC Wainwright & Co.
Yi Chen
 → $25Reiterates → BuyGet Alert
03/03/2023Buy Now145.33%Chardan Capital
Daniil Gataulin
 → $21Reiterates → BuyGet Alert
03/03/2023Buy Now192.06%HC Wainwright & Co.
Yi Chen
 → $25Reiterates → BuyGet Alert
02/28/2023Buy Now192.06%HC Wainwright & Co.
Yi Chen
 → $25Reiterates → BuyGet Alert
11/11/2022Buy Now507.48%Guggenheim
Yatin Suneja
$60 → $52MaintainsBuyGet Alert
08/04/2022Buy Now192.06%HC Wainwright & Co.
Yi Chen
$24 → $25MaintainsBuyGet Alert
07/07/2022Buy Now145.33%Chardan Capital
Daniil Gataulin
 → $21Initiates → BuyGet Alert
11/15/2021Buy Now180.37%HC Wainwright & Co.
Yi Chen
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for EyePoint Pharmaceuticals (EYPT) stock?

A

The latest price target for EyePoint Pharmaceuticals (NASDAQ:EYPT) was reported by Chardan Capital on June 28, 2024. The analyst firm set a price target for $28.00 expecting EYPT to rise to within 12 months (a possible 227.10% upside). 23 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for EyePoint Pharmaceuticals (EYPT)?

A

The latest analyst rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) was provided by Chardan Capital, and EyePoint Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for EyePoint Pharmaceuticals (EYPT)?

A

There is no last upgrade for EyePoint Pharmaceuticals

Q

When was the last downgrade for EyePoint Pharmaceuticals (EYPT)?

A

There is no last downgrade for EyePoint Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for EyePoint Pharmaceuticals (EYPT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of EyePoint Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for EyePoint Pharmaceuticals was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.

Q

Is the Analyst Rating EyePoint Pharmaceuticals (EYPT) correct?

A

While ratings are subjective and will change, the latest EyePoint Pharmaceuticals (EYPT) rating was a maintained with a price target of $28.00 to $28.00. The current price EyePoint Pharmaceuticals (EYPT) is trading at is $8.56, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch